Keyword: Mission Therapeutics
AbbVie and Mission Therapeutics inked an R&D pact focused on deubiquitylating enzymes in Alzheimer’s and Parkinson’s disease.
In this week's EuroBiotech Report, Europe-wide scrap for EMA intensifies, Vifor goes solo post-IPO, Mission bags Fox funding and more.
Mission Therapeutics and the University of Oxford have landed a Michael J. Fox Foundation grant to fund testing of USP30 inhibitors.